Silas was born with Netherton Syndrome, a devastating disease with no approved treatment. His story shows resilience + hope. Through #NETHERTONNOW, we share voices like his as we advance QRX003 — because everyone deserves to feel comfortable in their own skin.

.@QuoinPharma $QNRX has released the fifth video in its https://t.co/skKzt0GezO series, featuring Allie and Kaleigh Fasanella, twin sisters living with Netherton Syndrome (NS). The episode illustrates their deeply personal account of how this rare genetic skin disorder has shaped

Did you know Netherton Syndrome affects just 1 in 100,000–200,000 people worldwide? This rare and devastating genetic skin disease can be fatal in infancy and persists throughout life. With no approved treatments, patients and families face overwhelming challenges every day. At

Quoin Pharmaceuticals has announced its NETHERTON NOW Campaign has surpassed 1M views and over 14M impressions worldwide. This milestone reflects how far the NETHERTON NOW campaign has come in raising awareness as a global platform that brings the harsh realities of living with

.@QuoinPharma $QNRX has released the fourth video in its NETHERTON NOW series, featuring Mandy Aldwin-Easton — a lifelong Netherton Syndrome (NS) patient, global advocate, and President of the European Network for Ichthyosis. The episode spotlights the unpredictable, often

.@QuoinPharma $QNRX is pleased to announce strong second quarter results for 2025, highlighted by continued clinical progress and key regulatory milestones for our lead asset QRX003 for the treatment of Netherton Syndrome, as well as expanding development efforts across our

Quoin Pharmaceuticals $QNRX will announce its second quarter financial results, next Thursday, August https://t.co/zaXcDZov61 more here:  https://t.co/EjBeJEuqe1

Quoin Pharmaceuticals $QNRX announced today a comprehensive update on its development pipeline. Lead candidate QRX003 continues to advance in two active registrational clinical studies for Netherton Syndrome. We remain on track to file an NDA in the second half of 2026. Positive

Failure to Thrive in Netherton Syndrome: A Critical Pediatric Concern Infants with Netherton Syndrome (NS) often face life-threatening challenges in their earliest days. Beyond the hallmark symptoms of fragile, peeling skin and persistent erythroderma, many experience failure to

.@QuoinPharma has released its third video for its NETHERTON NOW campaign showcasing Professor Jemima Mellerio, a globally recognized expert in genetic skin disorders. The video sheds light on the severe impact of Netherton Syndrome, particularly in infants and young children,

.@QuoinPharma $QNRX has secured FDA Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome. The Quoin team is fully focused on completing our pivotal clinical studies and advancing QRX003 towards a New Drug Application as the first potential treatment for this

.@QuoinPharma $QNRX has announced another important and significant milestone receiving U.S. FDA clearance to initiate its second pivotal clinical study, CL-QRX003-002, for the treatment of Netherton Syndrome using QRX003. Quoin is the only company conducting two late-stage

.@QuoinPharma $QNRX announced lead candidate QRX003 has received Orphan Drug Designation from the European Medicines Agency (EMA) for the treatment of Netherton Syndrome. We continue to make important clinical and regulatory progress for QRX003 as a potential treatment for

.@QuoinPharma $QNRX is pleased to announce Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study. Read more here: https://t.co/wrr9zYrKwX #investors